Cardio-Oncology – Medxy AI

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients

By MedXY 03/09/2026

A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for differential cardiovascular risk between ADT classes.

Cardiology news Oncology

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

By MedXY 03/01/2026

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hit, unmasking latent vascular susceptibility in at-risk populations.

Cardiology news Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

By MedXY 02/19/2026

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offering a potential biological explanation for differential cardiovascular risks.

Cardiology news Oncology

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

By MedXY 02/09/2026

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

Clinical Updates news

Deciphering the Reversible Cardiotoxicity of Osimertinib: The Role of the GATA4-MYLK3-MYL2 Axis

By MedXY 01/02/2026

A breakthrough study reveals that osimertinib-induced cardiac dysfunction is driven by reversible sarcomere disarray via the GATA4-MYLK3-MYL2 signaling axis, suggesting that myosin activators could mitigate heart failure risk in lung cancer patients.

Cardiology news Oncology

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY 12/25/2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratification models in cardio-oncology.

Cardiology news Oncology

Sacubitril-Valsartan Prevents Anthracycline-Induced Myocardial Dysfunction: Results from the SARAH Trial

By MedXY 12/24/2025

The SARAH trial demonstrates that sacubitril-valsartan significantly reduces subclinical left ventricular dysfunction in patients with elevated troponin during anthracycline chemotherapy, potentially offering a new cardioprotective strategy for high-risk oncology patients.

Cardiology news Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

By MedXY 11/19/2025

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Trial selection and monitoring practices limit generalizability; baseline cardiac assessment and individualized surveillance remain essential.

Cardiology news Oncology

Managing Heart Risk from Cancer Immunotherapy: The International Cardio-Oncology Society Position on ICI-Associated Cardiovascular Toxicity

By MedXY 11/13/2025

An expert summary of the 2025 ICS position statement on immune checkpoint inhibitor–associated cardiovascular toxic effects, with practical diagnostic and treatment guidance for clinicians and researchers.

Cardiology news Oncology

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

By MedXY 10/24/2025

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.